Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9700523-B2
Publication Date
2017-07-11
Expiration Date
Abstract
An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer.
Core Innovation
An oxygen therapeutic composition is described that includes water, a perfluorocarbon material selected from perfluoropentane and perfluorohexane, sucrose, and a buffer. The buffer comprises NaH2PO4 and Na2HPO4 and stabilizes a pH of the composition between about 6.5 and about 7.5. The composition is formulated to comprise a viscosity of about 2.0 to about 3.5 mPas.
The disclosure emphasizes that the phosphate buffer comprising NaH2PO4 and Na2HPO4 stabilizes viscosity and prevents osmotic concentration increase over time. Sucrose is identified as a viscosity enhancer, and viscosity loss in unbuffered formulations is linked to sucrose breakdown to fructose and glucose.
A homogenized emulsion is also described as contained in a closed vial. The emulsion includes water, a perfluorocarbon material selected from perfluoropentane and perfluorohexane, glycerol, propylene glycol, and a buffer comprising NaH2PO4 and Na2HPO4, and further includes dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylethanolamine with covalently linked poly(ethylene glycol) molecular mass 5000.
Claims Coverage
The content includes two independent claims. Across these claims, the inventive features cover an oxygen therapeutic composition with a sucrose-containing phosphate-buffered formulation at a defined pH and viscosity, and a homogenized emulsion in a closed vial with specific formulation constituents including PEG-linked lipids and a NaH2PO4/Na2HPO4 buffer.
Phosphate-buffered oxygen therapeutic composition with sucrose and defined pH and viscosity
An oxygen therapeutic composition comprising water, a perfluorocarbon material selected from perfluoropentane and perfluorohexane, sucrose, and a buffer wherein the buffer comprises NaH2PO4 and Na2HPO4 to stabilize a pH of the composition between about 6.5 and about 7.5, and wherein the composition comprises a viscosity of about 2.0 to about 3.5 mPas.
Closed-vial homogenized emulsion with PEG-linked phospholipids and phosphate buffer
A homogenized emulsion contained in a closed vial, comprising water, a perfluorocarbon material selected from perfluoropentane and perfluorohexane, glycerol, propylene glycol, a buffer comprising NaH2PO4 and Na2HPO4, dipalmitoylphosphatidylcholine, and dipalmitoylphosphatidylethanolamine with covalently linked poly(ethylene glycol) molecular mass 5000.
Claim coverage is anchored by two independent formulations: a sucrose-containing oxygen therapeutic composition with NaH2PO4/Na2HPO4 buffering to stabilize pH and achieve viscosity, and a closed-vial homogenized emulsion including a NaH2PO4/Na2HPO4 buffer, glycerol/propylene glycol, and PEG-linked phosphatidylethanolamine together with dipalmitoylphosphatidylcholine and a perfluorocarbon selected from perfluoropentane or perfluorohexane.
Stated Advantages
The phosphate buffer stabilizes viscosity and prevents osmotic concentration increase over time.
Documented Applications
Oxygen therapeutic composition and homogenized emulsion for oxygen therapeutic use, formulated as described and contained in a closed vial.
Interested in licensing this patent?